-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Eratum: Clin Invest (2014) 4(2), 227-234.
Erratum: Clinical Investigation
-
Eratum: Clin Invest (2014) 4(2), 227-234.
Erratum: Clinical Investigation
-
Eratum: Clin Invest (2014) 4(2), 227-234.
Erratum: Clinical Investigation
-
Eratum: Clin Invest (2014) 4(2), 227-234.
Erratum: Clinical Investigation
-
Eratum: Clin Invest (2014) 4(2), 227-234.
Erratum: Clinical Investigation
-
Eratum: Clin Invest (2014) 4(2), 227-234.
Erratum: Clinical Investigation
-
Eratum: Clin Invest (2014) 4(2), 227-234.
Erratum: Clinical Investigation
-
Eratum: Clin Invest (2014) 4(2), 227-234.
Erratum: Clinical Investigation
-
Development of a cross-pharmaceutical database: a paradigm change for accelerating the drug-development process
Larry Alphsclinical trials , database , drug development ,neuropsychiatric ,pharmaceutical
Editorial: Clinical Investigation
-
Development of a cross-pharmaceutical database: a paradigm change for accelerating the drug-development process
Larry Alphsclinical trials , database , drug development ,neuropsychiatric ,pharmaceutical
Editorial: Clinical Investigation
-
Development of a cross-pharmaceutical database: a paradigm change for accelerating the drug-development process
Larry Alphsclinical trials , database , drug development ,neuropsychiatric ,pharmaceutical
Editorial: Clinical Investigation
-
Development of a cross-pharmaceutical database: a paradigm change for accelerating the drug-development process
Larry Alphsclinical trials , database , drug development ,neuropsychiatric ,pharmaceutical
Editorial: Clinical Investigation
-
Development of a cross-pharmaceutical database: a paradigm change for accelerating the drug-development process
Larry Alphsclinical trials , database , drug development ,neuropsychiatric ,pharmaceutical
Editorial: Clinical Investigation
-
Development of a cross-pharmaceutical database: a paradigm change for accelerating the drug-development process
Larry Alphsclinical trials , database , drug development ,neuropsychiatric ,pharmaceutical
Editorial: Clinical Investigation
-
Development of a cross-pharmaceutical database: a paradigm change for accelerating the drug-development process
Larry Alphsclinical trials , database , drug development ,neuropsychiatric ,pharmaceutical
Editorial: Clinical Investigation
-
Development of a cross-pharmaceutical database: a paradigm change for accelerating the drug-development process
Larry Alphsclinical trials , database , drug development ,neuropsychiatric ,pharmaceutical
Editorial: Clinical Investigation
-
The unfolding treatment landscape for men with astration-resistant prostate cancer
Jenny J Kim, Daniel Keizman, Samuel R Denmeade,Emmanuel S Antonarakis
Review Article: Clinical Investigation
-
The unfolding treatment landscape for men with astration-resistant prostate cancer
Jenny J Kim, Daniel Keizman, Samuel R Denmeade,Emmanuel S Antonarakis
Review Article: Clinical Investigation
-
The unfolding treatment landscape for men with astration-resistant prostate cancer
Jenny J Kim, Daniel Keizman, Samuel R Denmeade,Emmanuel S Antonarakis
Review Article: Clinical Investigation
-
The unfolding treatment landscape for men with astration-resistant prostate cancer
Jenny J Kim, Daniel Keizman, Samuel R Denmeade,Emmanuel S Antonarakis
Review Article: Clinical Investigation
-
The unfolding treatment landscape for men with astration-resistant prostate cancer
Jenny J Kim, Daniel Keizman, Samuel R Denmeade,Emmanuel S Antonarakis
Review Article: Clinical Investigation
-
The unfolding treatment landscape for men with astration-resistant prostate cancer
Jenny J Kim, Daniel Keizman, Samuel R Denmeade,Emmanuel S Antonarakis
Review Article: Clinical Investigation
-
The unfolding treatment landscape for men with astration-resistant prostate cancer
Jenny J Kim, Daniel Keizman, Samuel R Denmeade,Emmanuel S Antonarakis
Review Article: Clinical Investigation
-
The unfolding treatment landscape for men with astration-resistant prostate cancer
Jenny J Kim, Daniel Keizman, Samuel R Denmeade,Emmanuel S Antonarakis
Review Article: Clinical Investigation